The application of COVID-19 convalescent plasma in clinical treatment
Yan Liu, Aiping Liu, Rong Wang, Changfeng Shao, Ping Li, Q. Ju, Shumin Chen, P. Zong, Li-Chao Wang, Haiyan Wang
{"title":"The application of COVID-19 convalescent plasma in clinical treatment","authors":"Yan Liu, Aiping Liu, Rong Wang, Changfeng Shao, Ping Li, Q. Ju, Shumin Chen, P. Zong, Li-Chao Wang, Haiyan Wang","doi":"10.21037/aob-21-18","DOIUrl":null,"url":null,"abstract":"The severe acute respiratory syndrome (SARS) coronavirus disease known as coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2 has caused a global pandemic since late 2019. As of 7 February 2020, more than 106 million people have been infected, and approximately 2,317 thousand people have died due to SARS-CoV-2 across 200 countries. Unfortunately, to date, many aspects of pathogenesis, infection, clinical manifestations and treatment methods remain unclear, no specific antiviral drugs or vaccines have been reported for patients with COVID-19 infection. Most patients with severe infections require supportive organ function therapies in the intensive care unit (ICU). Passive antibody therapies such as convalescent plasma (CP) therapy have been proved to be effective in the treatment of many infectious diseases such as SARS and Middle East respiratory syndrome (MERS), which are also assumed as a promising strategy in the treatment of critically ill COVID-19 patients. With the increasing investigation, the objective understanding of COVID-19 prevention, treatment and comorbid disease is beneficial for the application of the strategy applied in the clinical trials. Herein, we briefly discuss the current therapeutic approaches for patients with COVID-19, especially focuses on the application of therapeutic plasma exchange (TPE) for selected critically ill patients, aiming to provide some guidance for the treatment of severe COVID-19. © Annals of Blood. All rights reserved.","PeriodicalId":72211,"journal":{"name":"Annals of blood","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of blood","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/aob-21-18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The severe acute respiratory syndrome (SARS) coronavirus disease known as coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2 has caused a global pandemic since late 2019. As of 7 February 2020, more than 106 million people have been infected, and approximately 2,317 thousand people have died due to SARS-CoV-2 across 200 countries. Unfortunately, to date, many aspects of pathogenesis, infection, clinical manifestations and treatment methods remain unclear, no specific antiviral drugs or vaccines have been reported for patients with COVID-19 infection. Most patients with severe infections require supportive organ function therapies in the intensive care unit (ICU). Passive antibody therapies such as convalescent plasma (CP) therapy have been proved to be effective in the treatment of many infectious diseases such as SARS and Middle East respiratory syndrome (MERS), which are also assumed as a promising strategy in the treatment of critically ill COVID-19 patients. With the increasing investigation, the objective understanding of COVID-19 prevention, treatment and comorbid disease is beneficial for the application of the strategy applied in the clinical trials. Herein, we briefly discuss the current therapeutic approaches for patients with COVID-19, especially focuses on the application of therapeutic plasma exchange (TPE) for selected critically ill patients, aiming to provide some guidance for the treatment of severe COVID-19. © Annals of Blood. All rights reserved.
新冠肺炎恢复期血浆在临床治疗中的应用
由SARS- cov -2引起的严重急性呼吸系统综合症(SARS)冠状病毒疾病,即冠状病毒病2019 (COVID-19),自2019年底以来引起了全球大流行。截至2020年2月7日,在200个国家,已有超过1.06亿人被感染,约有231.7万人死于SARS-CoV-2。遗憾的是,迄今为止,COVID-19的发病机制、感染、临床表现和治疗方法等许多方面仍不清楚,没有针对COVID-19感染患者的特异性抗病毒药物或疫苗的报道。大多数严重感染患者需要在重症监护病房(ICU)进行支持性器官功能治疗。康复期血浆(CP)治疗等被动抗体疗法已被证明对SARS、中东呼吸综合征(MERS)等多种传染病的治疗有效,也被认为是治疗COVID-19危重症患者的有希望的策略。随着调查的不断增多,对COVID-19的预防、治疗和合并症的客观认识,有利于临床试验中应用的策略的应用。本文简要讨论当前新冠肺炎患者的治疗方法,重点介绍治疗性血浆置换(TPE)在部分危重患者中的应用,旨在为重症患者的治疗提供一定的指导。©Annals of Blood。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。